EW

Edwards Lifesciences
D

EW

Arincen78/100B
107.380
USD
1.54
(1.46%)
Market Open
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.66Revenue estimate 1.71B
OverviewFinancialsForecastEarningsCompany

Edwards Lifesciences executives and insider trading

Bernard J. Zovighian sold 110,675 shares for 9.38M USD in 10 sales over the last twelve months, the last on 9 November 2026, and bought none on the open market.

Over the last twelve months Edwards Lifesciences's insiders sold 390,783 shares for 34.06M USD in 55 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
55
Shares sold
390,783
Value sold
34.06M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
7.48M USD
0
1 month
7.48M USD
0
3 months
10.89M USD
0
6 months
15.88M USD
0
1 year
34.06M USD
0
2 years
47.95M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Bernard J. Zovighian CEOChief Executive Officer & Director58110,6759.38M USD—9 Nov 2026121,945
Donald E. Bobo Jr. Corporate Vice President of Strategy & Corporate Development64182,09916.19M USD—9 Nov 202671,698
Daveen Chopra Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies4735,3003.19M USD—26 Aug 202643,926
Scott B. Ullem CVP, Chief Financial Officer—33,7002.79M USD—9 Apr 202657,744
Wayne Markowitz CVP, JAPAC—12,1901.04M USD—26 Aug 202619,371
Daniel J. Lippis CVP, TAVR—10,448904.97K USD—10 Nov 202640,653
Annette Maria Bruls Corporate Vice President of EMEA, Canada, & Latin America552,644237.91K USD—28 Aug 202617,984
Heisz Leslie Stone Director—2,615218.12K USD—12 Dec 202534,199
Andrew Dahl Principal Accounting Officer, Senior Vice President & Corporate Controller481,11298.39K USD—31 Aug 202614,615

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
10 Nov 2026Daniel J. LippisSale619104.2564.53K USD40,034Form 4
9 Nov 2026Bernard J. ZovighianSale9,184103.39949.49K USD112,761Form 4
9 Nov 2026Bernard J. ZovighianSale13,916102.781.43M USD98,845Form 4
9 Nov 2026Donald E. Bobo Jr.Sale48,900103.055.04M USD22,798Form 4
8 Oct 2026Daniel J. LippisSale61985.6553.02K USD40,034Form 4
11 Sept 2026Daniel J. LippisSale61987.5154.17K USD40,034Form 4
31 Aug 2026Andrew DahlSale54491.0649.53K USD14,868Form 4
28 Aug 2026Annette Maria BrulsSale2,64489.98237.91K USD17,984Form 4
26 Aug 2026Daveen ChopraSale1,15491.76105.89K USD74,970Form 4
26 Aug 2026Daveen ChopraSale30,64690.992.79M USD44,324Form 4
26 Aug 2026Wayne MarkowitzSale1,24091.47113.42K USD20,294Form 4
11 Aug 2026Daniel J. LippisSale61992.0356.97K USD40,034Form 4
30 Jul 2026Wayne MarkowitzSale14686.0312.59K USD21,534Form 4
28 Jul 2026Wayne MarkowitzSale9,62885.06818.96K USD21,680Form 4
27 Jul 2026Bernard J. ZovighianSale2,92183.93245.13K USD8,916Form 4

Common questions about Edwards Lifesciences's executives and insiders

Source: Financial Modeling Prep